Literature DB >> 16633062

Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.

Jong-Shiaw Jin1, Chen-Wen Yao, Shih-Hurng Loh, Ming-Fang Cheng, Dar-Shih Hsieh, Chien-Yu Bai.   

Abstract

Ovary cancer invasion is responsible for both local tissue destruction and distant metastasis. Invasion is largely mediated by matrix metalloproteases that are thought to be induced by tumor cell-derived extracellular matrix metalloprotease inducer (EMMPRIN) in surrounding fibroblasts. We hypothesized that EMMPRIN isoverexpressed in ovary tumors. Immunohistochemical analysis of EMMPRIN was performed in tissue microarrays of ovary neoplasms including 84 cases of serous adenocarcinoma, 23 cases of mucinous adenocarcinoma, 10 cases of endometrioid adenocarcinoma, 12 cases of yolk sac tumor, 12 cases of clear cell carcinoma, 8 cases of dysgerminoma, 8 cases of granulosa cell tumor, 6 cases of transitional cell carcinoma, and 6 cases of Brenner tumor. All malignant ovary tumors showed significant immunohistochemical expression of EMMPRIN. The EMMPRIN scores in malignant ovary tumors were significantly higher than their nontumor counterparts (313+/-28 for serous adenocarcinoma; 308+/-25 for mucinous adenocarcinoma; 187+/-19 for endometrioid adenocarcinoma; 265+/-23 for yolk sac tumors; 87+/-13 for clear cellcarcinoma; 126+/-15 for dysgerminoma; 243+/-26 for granulosa cell tumor; 87+/-16 for transitional cell carcinoma). The EMMPRIN score was significantly higher in serous adenocarcinomas than in serous adenomas and serous borderline tumors and was correlated with nodal stage. Our findings show for the first time that EMMPRIN is overexpressed in all malignant ovary tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16633062     DOI: 10.1097/01.pgp.0000189244.57145.84

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  11 in total

1.  CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer.

Authors:  Yi-Jun Xue; Qiang Lu; Zhi-Xi Sun
Journal:  Med Oncol       Date:  2010-05-28       Impact factor: 3.064

2.  Expression of basigin in reproductive tissues of estrogen receptor-{alpha} or -{beta} null mice.

Authors:  Li Chen; Jiajia Bi; Masaaki Nakai; David Bunick; John F Couse; Kenneth S Korach; Romana A Nowak
Journal:  Reproduction       Date:  2010-04-13       Impact factor: 3.906

3.  Hispidulin induces mitochondrial apoptosis in acute myeloid leukemia cells by targeting extracellular matrix metalloproteinase inducer.

Authors:  Hui Gao; Yongji Liu; Kan Li; Tianhui Wu; Jianjun Peng; Fanbo Jing
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 4.  EMMPRIN in gynecologic cancers: pathologic and therapeutic aspects.

Authors:  Dan-tong Liu
Journal:  Tumour Biol       Date:  2015-05-14

5.  Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression.

Authors:  Hongmin Chen; Li Wang; Julia Beretov; Jingli Hao; Weiwei Xiao; Yong Li
Journal:  Clin Exp Metastasis       Date:  2010-07-24       Impact factor: 5.150

6.  Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma.

Authors:  Xin-Qiong Huang; Xiang Chen; Xiao-Xue Xie; Qin Zhou; Kai Li; Shan Li; Liang-Fang Shen; Juan Su
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 7.  CD147 immunoglobulin superfamily receptor function and role in pathology.

Authors:  Kathryn T Iacono; Amy L Brown; Mark I Greene; Sandra J Saouaf
Journal:  Exp Mol Pathol       Date:  2007-09-07       Impact factor: 3.362

8.  Role of emmprin in endometrial cancer.

Authors:  Keiichiro Nakamura; Junichi Kodama; Atsushi Hongo; Yuji Hiramatsu
Journal:  BMC Cancer       Date:  2012-05-28       Impact factor: 4.430

9.  EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.

Authors:  Mototaka Sato; Yasutomo Nakai; Wataru Nakata; Takahiro Yoshida; Koji Hatano; Atsunari Kawashima; Kazutoshi Fujita; Motohide Uemura; Hitoshi Takayama; Norio Nonomura
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

Review 10.  Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis.

Authors:  Sigrid Marie Kraggerud; Christina E Hoei-Hansen; Sharmini Alagaratnam; Rolf I Skotheim; Vera M Abeler; Ewa Rajpert-De Meyts; Ragnhild A Lothe
Journal:  Endocr Rev       Date:  2013-04-10       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.